It is well‐established that glycolytic inhibitors (such as 2DG) selectively induce apoptosis in glucose‐dependent cancer cells with overactive RAS and AKT oncogenes (Kroemer & Pouyssegur, 2008). The gene discussed is AKT1; the disease is cancer.